Infliximab in primary Sjögren's syndrome: one-year followup.
OBJECTIVE
To evaluate the safety and efficacy of a maintenance regimen of infliximab in patients with active primary Sjögren's syndrome (SS) over a 1-year period.


METHODS
This followup study included 10 of the 16 patients with primary SS who participated in a pilot study. Patients who continued to have symptoms received additional infusions of infliximab for 1 year.


RESULTS
All patients completed the 1-year followup for evaluation of efficacy. After 1 year, a statistically significant decrease in global and local disease manifestations was observed in all 10 patients. Treatment was generally well tolerated, with the main side effect being a mild, self-limited infusion reaction.


CONCLUSIONS
Sustained improvement of active primary SS may be possible with infliximab treatment.
Steinfeld
Serge D
SD
Department of Rheumatology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. ssteinfe@ulb.ac.be
Demols
Paul
P
Appelboom
Thierry
T
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D010865:Pilot Projects; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab